Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Marks First Commercial Use of Low-Enriched Uranium-based Molybdenum-99 in the U.S.

Demonstrates Company’s Ongoing Leadership and Commitment to Supply Chain Diversification Strategy and Global Nuclear Security

Lantheus Medical Imaging , Inc., a worldwide leader in diagnostic medical imaging, announced the first commercial production of TechneLite® (Technetium Tc99m Generator) generators using molybdenum-99 (Mo-99) produced with low-enriched uranium (LEU) targets, making Lantheus the first company to use Mo-99 sourced from LEU in the United States. Lantheus Medical Imaging received the first commercial scale batch from NTP Radioisotopes Ltd. (NTP), a subsidiary of the Nuclear Energy Corporate of South Africa (NESCA).

As a global leader in the medical imaging industry, Lantheus Medical Imaging is working closely with NTP and the Department of Energy as part of the Global Threat Reduction Initiative to drive the conversion of production of Mo-99, an important medical isotope, from the use of highly-enriched uranium (HEU) to LEU. This announcement marks a major accomplishment in global nuclear security and supports the United States’ non-proliferation efforts to minimize and eventually eliminate all commercial use of HEU.

“ Lantheus Medical Imaging is a leader in securing and supplying Mo-99 to the nuclear medicine community and we are pleased to be the first company in North America to receive FDA approval for the commercial sale and distribution of our TechneLite® generators using Mo-99 produced from LEU targets,” said Don Kiepert, President and Chief Executive Officer, Lantheus Medical Imaging . “Today’s announcement demonstrates our commitment to working with government officials, such as NNSA, to promote global nuclear safety by providing a new, secure approach to producing Mo-99.

“We proactively implemented a diversification strategy for the supply of Mo-99 several years ago to increase reliable access to this key medical isotope,” continued Kiepert. “The use of LEU-sourced Mo-99 further demonstrates our commitment to providing the health care community with secure, uninterrupted and timely access to critical medical imaging procedures, allowing health care providers to make more informed and better therapeutic decisions for their patients. As a result, we believe more patients will receive more appropriate levels of care, potentially improving outcomes, reducing patient risk and decreasing costs for the entire health care system.”

As a result of the recent and prolonged global supply shortage of Mo-99 and the Company’s global supply chain diversification strategy, Lantheus Medical Imaging entered into an agreement with NTP in 2009 in an effort to ensure expanded access to Mo-99 and has been working closely with NTP to qualify LEU-based Mo-99 for commercial use. While Lantheus’ current supply of Mo-99 is sufficient to meet current and near-term needs, the Company continues to pursue various initiatives to ensure a global diversified and reliable source of Mo-99, including identifying potential new producers as well as new technologies such as LEU-produced Mo-99.

Source: Lantheus Medical Imaging , Inc.